Skip to main content
Erschienen in:

18.04.2024 | Review Article

Inflammatory Gene Panel Guiding the Study of Genetics in Inflammatory Bowel Disease

verfasst von: Ryan Xin

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel disease (IBD) is a complex disease that develops through a sequence of molecular events that are still poorly defined. This process is driven by a multitude of context-dependent genes that play different roles based on their environment. The complexity and multi-faceted nature of these genes make it difficult to study the genetic basis of IBD. The goal of this article is to review the key genes in the pathophysiology of IBD and highlight new technology that can be used in further research. This paper examines Nanostring RNA probe technology, which uses tissue analyzed without the use of enzymes, transcription, or amplification. Nanostring offers several panels of genes to test, including an inflammation panel of 234 genes. This article analyzes this panel and reviews the literature for each gene’s effect in IBD for use as a framework to review the pathophysiology of the disease. The panel was narrowed to 26 genes with significant evidence of mechanistic potential in IBD, which were then categorized into specific areas of pathogenesis. These include gut barrier breakdown, inappropriate recognition of commensal bacteria, immune cell activation, proinflammatory cytokine release, and subsequent impairment of the anti-inflammatory response. The eventual goal of this paper is the creation of a customized panel of IBD genes that can be used to better understand the genetic mechanism of IBD and aid in the development of future therapies in IBD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Collaborators GIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.CrossRef Collaborators GIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.CrossRef
2.
Zurück zum Zitat Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66.PubMedCrossRef Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66.PubMedCrossRef
3.
Zurück zum Zitat Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology. 2007;133:1327–39.PubMedCrossRef Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology. 2007;133:1327–39.PubMedCrossRef
4.
Zurück zum Zitat Dheer R, Davies JM, Quintero MA, et al. Microbial signatures and innate immune gene expression in lamina propria phagocytes of inflammatory bowel disease patients. Cell Mol Gastroenterol Hepatol. 2020;9:387–402.PubMedCrossRef Dheer R, Davies JM, Quintero MA, et al. Microbial signatures and innate immune gene expression in lamina propria phagocytes of inflammatory bowel disease patients. Cell Mol Gastroenterol Hepatol. 2020;9:387–402.PubMedCrossRef
5.
Zurück zum Zitat Rankin CR, Shao L, Elliott J, et al. The IBD-associated long noncoding RNA IFNG-AS1 regulates the balance between inflammatory and anti-inflammatory cytokine production after T-cell stimulation. Am J Physiol Gastrointest Liver Physiol. 2020;318:G34-40.PubMedCrossRef Rankin CR, Shao L, Elliott J, et al. The IBD-associated long noncoding RNA IFNG-AS1 regulates the balance between inflammatory and anti-inflammatory cytokine production after T-cell stimulation. Am J Physiol Gastrointest Liver Physiol. 2020;318:G34-40.PubMedCrossRef
6.
Zurück zum Zitat Okada K, Okabe M, Kimura Y, et al. Serum S100A8/A9 as a potentially sensitive biomarker for inflammatory bowel disease. Lab Med. 2019;50:370–80.PubMedCrossRef Okada K, Okabe M, Kimura Y, et al. Serum S100A8/A9 as a potentially sensitive biomarker for inflammatory bowel disease. Lab Med. 2019;50:370–80.PubMedCrossRef
7.
Zurück zum Zitat Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29:2035–43.PubMedPubMedCentralCrossRef Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29:2035–43.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Body-Malapel M, Djouina M, Waxin C, et al. The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for inflammatory bowel diseases. Mucosal Immunol. 2019;12:468–78.PubMedCrossRef Body-Malapel M, Djouina M, Waxin C, et al. The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for inflammatory bowel diseases. Mucosal Immunol. 2019;12:468–78.PubMedCrossRef
9.
Zurück zum Zitat Borcherding F, Nitschke M, Hundorfean G, et al. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol. 2010;176:1816–27.PubMedPubMedCentralCrossRef Borcherding F, Nitschke M, Hundorfean G, et al. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am J Pathol. 2010;176:1816–27.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Danese S, Scaldaferri F, Vetrano S, et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut. 2007;56:1248–56.PubMedPubMedCentralCrossRef Danese S, Scaldaferri F, Vetrano S, et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut. 2007;56:1248–56.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Vowinkel T, Anthoni C, Wood KC, et al. CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterology. 2007;132:955–65.PubMedCrossRef Vowinkel T, Anthoni C, Wood KC, et al. CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterology. 2007;132:955–65.PubMedCrossRef
13.
Zurück zum Zitat Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis. 2003;18:142–7.PubMedCrossRef Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis. 2003;18:142–7.PubMedCrossRef
14.
Zurück zum Zitat Liu Z, Colpaert S, D’Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999;163:4049–57.PubMedCrossRef Liu Z, Colpaert S, D’Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999;163:4049–57.PubMedCrossRef
15.
Zurück zum Zitat Scarpa M, Behboo R, Angriman I, et al. The role of costimulatory molecules CD80 and CD86 and IFNgamma in the pathogenesis of ulcerative colitis. Dig Dis Sci. 2004;49:1738–44.PubMedCrossRef Scarpa M, Behboo R, Angriman I, et al. The role of costimulatory molecules CD80 and CD86 and IFNgamma in the pathogenesis of ulcerative colitis. Dig Dis Sci. 2004;49:1738–44.PubMedCrossRef
16.
Zurück zum Zitat Grose RH, Howarth GS, Xian CJ, et al. Expression of B7 costimulatory molecules by cells infiltrating the colon in experimental colitis induced by oral dextran sulfate sodium in the mouse. J Gastroenterol Hepatol. 2001;16:1228–34.PubMedCrossRef Grose RH, Howarth GS, Xian CJ, et al. Expression of B7 costimulatory molecules by cells infiltrating the colon in experimental colitis induced by oral dextran sulfate sodium in the mouse. J Gastroenterol Hepatol. 2001;16:1228–34.PubMedCrossRef
17.
Zurück zum Zitat Baumgart DC, Metzke D, Schmitz J, et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut. 2005;54:228–36.PubMedPubMedCentralCrossRef Baumgart DC, Metzke D, Schmitz J, et al. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut. 2005;54:228–36.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Ostvik AE, Granlund AV, Bugge M, et al. Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation. Inflamm Bowel Dis. 2013;19:265–74.PubMedCrossRef Ostvik AE, Granlund AV, Bugge M, et al. Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation. Inflamm Bowel Dis. 2013;19:265–74.PubMedCrossRef
19.
Zurück zum Zitat Singh UP, Singh S, Singh R, et al. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008;28:31–43.PubMedCrossRef Singh UP, Singh S, Singh R, et al. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008;28:31–43.PubMedCrossRef
20.
Zurück zum Zitat Hyun JG, Lee G, Brown JB, et al. Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis. 2005;11:799–805.PubMedCrossRef Hyun JG, Lee G, Brown JB, et al. Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis. 2005;11:799–805.PubMedCrossRef
21.
Zurück zum Zitat Hosomi S, Oshitani N, Kamata N, et al. Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. Clin Exp Immunol. 2011;163:215–24.PubMedPubMedCentralCrossRef Hosomi S, Oshitani N, Kamata N, et al. Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. Clin Exp Immunol. 2011;163:215–24.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Mikami S, Nakase H, Yamamoto S, et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther. 2008;327:383–92.PubMedCrossRef Mikami S, Nakase H, Yamamoto S, et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther. 2008;327:383–92.PubMedCrossRef
23.
Zurück zum Zitat Uo M, Hisamatsu T, Miyoshi J, et al. Mucosal CXCR4<sup>+</sup> IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut. 2013;62:1734–44.PubMedCrossRef Uo M, Hisamatsu T, Miyoshi J, et al. Mucosal CXCR4<sup>+</sup> IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut. 2013;62:1734–44.PubMedCrossRef
24.
25.
Zurück zum Zitat Palone F, Vitali R, Cucchiara S, et al. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission. Inflamm Bowel Dis. 2016;22:2886–93.PubMedCrossRef Palone F, Vitali R, Cucchiara S, et al. Fecal HMGB1 reveals microscopic inflammation in adult and pediatric patients with inflammatory bowel disease in clinical and endoscopic remission. Inflamm Bowel Dis. 2016;22:2886–93.PubMedCrossRef
26.
Zurück zum Zitat Palone F, Vitali R, Cucchiara S, et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1448–57.PubMedCrossRef Palone F, Vitali R, Cucchiara S, et al. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1448–57.PubMedCrossRef
27.
Zurück zum Zitat Chen X, Li L, Khan MN, et al. HMGB1 exacerbates experimental mouse colitis by enhancing innate lymphoid cells 3 inflammatory responses via promoted IL-23 production. Innate Immun. 2016;22:696–705.PubMedCrossRef Chen X, Li L, Khan MN, et al. HMGB1 exacerbates experimental mouse colitis by enhancing innate lymphoid cells 3 inflammatory responses via promoted IL-23 production. Innate Immun. 2016;22:696–705.PubMedCrossRef
28.
29.
Zurück zum Zitat Mavropoulou E, Mechie NC, Knoop R, et al. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: a prospective observational study. PLoS ONE. 2020;15: e0233811.PubMedPubMedCentralCrossRef Mavropoulou E, Mechie NC, Knoop R, et al. Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: a prospective observational study. PLoS ONE. 2020;15: e0233811.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164:4878–82.PubMedCrossRef Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol. 2000;164:4878–82.PubMedCrossRef
31.
Zurück zum Zitat Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583–8.PubMedCrossRef Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583–8.PubMedCrossRef
32.
Zurück zum Zitat Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68:40–8.PubMedCrossRef Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68:40–8.PubMedCrossRef
33.
Zurück zum Zitat Schreiber S, Aden K, Bernardes JP, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterolgy. 2021;160:2354-66.e2311.CrossRef Schreiber S, Aden K, Bernardes JP, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterolgy. 2021;160:2354-66.e2311.CrossRef
34.
Zurück zum Zitat Li L, Huang S, Wang H, et al. Cytokine IL9 triggers the pathogenesis of inflammatory bowel disease through the miR21-CLDN8 pathway. Inflamm Bowel Dis. 2018;24:2211–23.PubMedCrossRef Li L, Huang S, Wang H, et al. Cytokine IL9 triggers the pathogenesis of inflammatory bowel disease through the miR21-CLDN8 pathway. Inflamm Bowel Dis. 2018;24:2211–23.PubMedCrossRef
35.
Zurück zum Zitat Tian L, Li Y, Zhang J, et al. IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling. Biosci Rep. 2018;38:BSR20181521.PubMedPubMedCentralCrossRef Tian L, Li Y, Zhang J, et al. IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling. Biosci Rep. 2018;38:BSR20181521.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Gomes-Santos AC, Moreira TG, Castro-Junior AB, et al. New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol. 2012;2012: 560817.PubMedPubMedCentralCrossRef Gomes-Santos AC, Moreira TG, Castro-Junior AB, et al. New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol. 2012;2012: 560817.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Veenbergen S, Li P, Raatgeep HC, et al. IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4(+) T cells: relevance to inflammatory bowel disease. Mucosal Immunol. 2019;12:1201–11.PubMedPubMedCentralCrossRef Veenbergen S, Li P, Raatgeep HC, et al. IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4(+) T cells: relevance to inflammatory bowel disease. Mucosal Immunol. 2019;12:1201–11.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Koelink PJ, Bloemendaal FM, Li B, et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut. 2020;69:1053–63.PubMedCrossRef Koelink PJ, Bloemendaal FM, Li B, et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut. 2020;69:1053–63.PubMedCrossRef
39.
Zurück zum Zitat Aschenbrenner D, Quaranta M, Banerjee S, et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut. 2021;70:1023–36.PubMedCrossRef Aschenbrenner D, Quaranta M, Banerjee S, et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut. 2021;70:1023–36.PubMedCrossRef
40.
Zurück zum Zitat Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014;40:706–19.PubMedPubMedCentralCrossRef Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014;40:706–19.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Shouval DS, Biswas A, Kang YH, et al. Interleukin 1β mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology. 2016;151:1100–4.PubMedCrossRef Shouval DS, Biswas A, Kang YH, et al. Interleukin 1β mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology. 2016;151:1100–4.PubMedCrossRef
42.
Zurück zum Zitat Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297–301.PubMedCrossRef Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297–301.PubMedCrossRef
43.
Zurück zum Zitat ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206–11.PubMedPubMedCentralCrossRef ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206–11.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Vos AC, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401–8.PubMedCrossRef Vos AC, Wildenberg ME, Arijs I, et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflamm Bowel Dis. 2012;18:401–8.PubMedCrossRef
45.
Zurück zum Zitat Dubé PE, Punit S, Polk DB. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2015;308:G161–70.PubMedCrossRef Dubé PE, Punit S, Polk DB. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2015;308:G161–70.PubMedCrossRef
46.
Zurück zum Zitat Hale LP, Greer PK. A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. PLoS ONE. 2012;7: e41797.PubMedPubMedCentralCrossRef Hale LP, Greer PK. A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. PLoS ONE. 2012;7: e41797.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Skovdahl HK, Damås JK, Granlund AVB, et al. C-C motif ligand 20 (CCL20) and C-C motif chemokine receptor 6 (CCR6) in human peripheral blood mononuclear cells: dysregulated in ulcerative colitis and a potential role for CCL20 in IL-1β release. Int J Mol Sci. 2018;19:3257.PubMedPubMedCentralCrossRef Skovdahl HK, Damås JK, Granlund AVB, et al. C-C motif ligand 20 (CCL20) and C-C motif chemokine receptor 6 (CCR6) in human peripheral blood mononuclear cells: dysregulated in ulcerative colitis and a potential role for CCL20 in IL-1β release. Int J Mol Sci. 2018;19:3257.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Marafini I, Monteleone I, Dinallo V, et al. CCL20 is negatively regulated by TGF-β1 in intestinal epithelial cells and reduced in Crohn’s disease patients with a successful response to mongersen, a Smad7 antisense oligonucleotide. J Crohns Colitis. 2017;11:603–9.PubMed Marafini I, Monteleone I, Dinallo V, et al. CCL20 is negatively regulated by TGF-β1 in intestinal epithelial cells and reduced in Crohn’s disease patients with a successful response to mongersen, a Smad7 antisense oligonucleotide. J Crohns Colitis. 2017;11:603–9.PubMed
49.
Zurück zum Zitat Katchar K, Kelly CP, Keates S, et al. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1263–71.PubMedCrossRef Katchar K, Kelly CP, Keates S, et al. MIP-3alpha neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1263–71.PubMedCrossRef
50.
Zurück zum Zitat Cook DN, Prosser DM, Forster R, et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 2000;12:495–503.PubMedCrossRef Cook DN, Prosser DM, Forster R, et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 2000;12:495–503.PubMedCrossRef
51.
Zurück zum Zitat Bouma G, Zamuner S, Hicks K, et al. CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6(+) cells in an experimental suction blister. Br J Clin Pharmacol. 2017;83:1976–90.PubMedPubMedCentralCrossRef Bouma G, Zamuner S, Hicks K, et al. CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6(+) cells in an experimental suction blister. Br J Clin Pharmacol. 2017;83:1976–90.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Smids C, Horjus Talabur Horje CS, Drylewicz J, et al. Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course. J Crohns Colitis. 2018;12:465–75.PubMedCrossRef Smids C, Horjus Talabur Horje CS, Drylewicz J, et al. Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease course. J Crohns Colitis. 2018;12:465–75.PubMedCrossRef
53.
Zurück zum Zitat Eri R, McGuckin MA, Wadley R. T cell transfer model of colitis: a great tool to assess the contribution of T cells in chronic intestinal inflammation. Methods Mol Biol. 2012;844:261–75.PubMedCrossRef Eri R, McGuckin MA, Wadley R. T cell transfer model of colitis: a great tool to assess the contribution of T cells in chronic intestinal inflammation. Methods Mol Biol. 2012;844:261–75.PubMedCrossRef
54.
Zurück zum Zitat Brasseit J, Althaus-Steiner E, Faderl M, et al. CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis. Mucosal Immunol. 2016;9:689–701.PubMedCrossRef Brasseit J, Althaus-Steiner E, Faderl M, et al. CD4 T cells are required for both development and maintenance of disease in a new mouse model of reversible colitis. Mucosal Immunol. 2016;9:689–701.PubMedCrossRef
55.
Zurück zum Zitat Shin B, Kress RL, Kramer PA, et al. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation. J Exp Med. 2018;215:1803–12.PubMedPubMedCentralCrossRef Shin B, Kress RL, Kramer PA, et al. Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation. J Exp Med. 2018;215:1803–12.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1α and 2α overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209–13.PubMedPubMedCentralCrossRef Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1α and 2α overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209–13.PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098–106.PubMedPubMedCentralCrossRef Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114:1098–106.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Kim YE, Lee M, Gu H, et al. HIF-1α activation in myeloid cells accelerates dextran sodium sulfate-induced colitis progression in mice. Dis Model Mech. 2018;11:dmm033241.PubMedPubMedCentralCrossRef Kim YE, Lee M, Gu H, et al. HIF-1α activation in myeloid cells accelerates dextran sodium sulfate-induced colitis progression in mice. Dis Model Mech. 2018;11:dmm033241.PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Kerber EL, Padberg C, Koll N, et al. The importance of hypoxia-inducible factors (HIF-1 and HIF-2) for the pathophysiology of inflammatory bowel disease. Int J Mol Sci. 2020;21:8551.PubMedPubMedCentralCrossRef Kerber EL, Padberg C, Koll N, et al. The importance of hypoxia-inducible factors (HIF-1 and HIF-2) for the pathophysiology of inflammatory bowel disease. Int J Mol Sci. 2020;21:8551.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Bäcker V, Cheung FY, Siveke JT, et al. Knockdown of myeloid cell hypoxia-inducible factor-1α ameliorates the acute pathology in DSS-induced colitis. PLoS ONE. 2017;12: e0190074.PubMedPubMedCentralCrossRef Bäcker V, Cheung FY, Siveke JT, et al. Knockdown of myeloid cell hypoxia-inducible factor-1α ameliorates the acute pathology in DSS-induced colitis. PLoS ONE. 2017;12: e0190074.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Flück K, Breves G, Fandrey J, et al. Hypoxia-inducible factor 1 in dendritic cells is crucial for the activation of protective regulatory T cells in murine colitis. Mucosal Immunol. 2016;9:379–90.PubMedCrossRef Flück K, Breves G, Fandrey J, et al. Hypoxia-inducible factor 1 in dendritic cells is crucial for the activation of protective regulatory T cells in murine colitis. Mucosal Immunol. 2016;9:379–90.PubMedCrossRef
62.
Zurück zum Zitat Lin N, Shay JES, Xie H, et al. Myeloid cell hypoxia-inducible factors promote resolution of inflammation in experimental colitis. Front Immunol. 2018;9:2565.PubMedPubMedCentralCrossRef Lin N, Shay JES, Xie H, et al. Myeloid cell hypoxia-inducible factors promote resolution of inflammation in experimental colitis. Front Immunol. 2018;9:2565.PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006;146:330–8.PubMedPubMedCentralCrossRef Ito R, Shin-Ya M, Kishida T, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006;146:330–8.PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Chiba H, Kojima T, Osanai M, et al. The significance of interferon-gamma-triggered internalization of tight-junction proteins in inflammatory bowel disease. Sci STKE. 2006;2006:pe1.PubMedCrossRef Chiba H, Kojima T, Osanai M, et al. The significance of interferon-gamma-triggered internalization of tight-junction proteins in inflammatory bowel disease. Sci STKE. 2006;2006:pe1.PubMedCrossRef
65.
Zurück zum Zitat Langer V, Vivi E, Regensburger D, et al. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J Clin Invest. 2019;129:4691–707.PubMedPubMedCentralCrossRef Langer V, Vivi E, Regensburger D, et al. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption. J Clin Invest. 2019;129:4691–707.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830–4.PubMedCrossRef Spadoni I, Zagato E, Bertocchi A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830–4.PubMedCrossRef
67.
Zurück zum Zitat Cui D, Huang G, Yang D, et al. Efficacy and safety of interferon-gamma-targeted therapy in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2013;37:507–13.PubMedCrossRef Cui D, Huang G, Yang D, et al. Efficacy and safety of interferon-gamma-targeted therapy in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2013;37:507–13.PubMedCrossRef
68.
Zurück zum Zitat Scarpa M, Kessler S, Sadler T, et al. The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol. 2015;185:1624–37.PubMedPubMedCentralCrossRef Scarpa M, Kessler S, Sadler T, et al. The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol. 2015;185:1624–37.PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Gionchetti P, Campieri M, Belluzzi A, et al. Interleukin 1 beta (IL-1 beta) release from fresh and cultured colonic mucosa in patients with ulcerative colitis (UC). Agents Actions. 1992;Spec No:C50–2. Gionchetti P, Campieri M, Belluzzi A, et al. Interleukin 1 beta (IL-1 beta) release from fresh and cultured colonic mucosa in patients with ulcerative colitis (UC). Agents Actions. 1992;Spec No:C50–2.
70.
Zurück zum Zitat Bersudsky M, Luski L, Fishman D, et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut. 2014;63:598–609.PubMedCrossRef Bersudsky M, Luski L, Fishman D, et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut. 2014;63:598–609.PubMedCrossRef
71.
Zurück zum Zitat Al-Sadi R, Ye D, Said HM, et al. IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. Am J Pathol. 2010;177:2310–22.PubMedPubMedCentralCrossRef Al-Sadi R, Ye D, Said HM, et al. IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. Am J Pathol. 2010;177:2310–22.PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Dosh RH, Jordan-Mahy N, Sammon C, et al. Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model. Oncotarget. 2019;10:3559–75.PubMedPubMedCentralCrossRef Dosh RH, Jordan-Mahy N, Sammon C, et al. Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model. Oncotarget. 2019;10:3559–75.PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Aschenbrenner D, Quaranta M, Banerjee S, et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut. 2020;70:1023.PubMedCrossRef Aschenbrenner D, Quaranta M, Banerjee S, et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut. 2020;70:1023.PubMedCrossRef
74.
Zurück zum Zitat Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–6.PubMedPubMedCentralCrossRef Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–6.PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Lee HW, Chung SH, Moon CM, et al. The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease. Medicine (Baltimore). 2016;95: e3772.PubMedCrossRef Lee HW, Chung SH, Moon CM, et al. The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease. Medicine (Baltimore). 2016;95: e3772.PubMedCrossRef
76.
Zurück zum Zitat Liu Z, Geboes K, Heremans H, et al. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. Eur J Immunol. 2001;31:1550–60.PubMedCrossRef Liu Z, Geboes K, Heremans H, et al. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. Eur J Immunol. 2001;31:1550–60.PubMedCrossRef
77.
Zurück zum Zitat Imamura E, Taguchi K, Sasaki-Iwaoka H, et al. Anti-IL-23 receptor monoclonal antibody prevents CD4(+) T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses. Eur J Pharmacol. 2018;824:163–9.PubMedCrossRef Imamura E, Taguchi K, Sasaki-Iwaoka H, et al. Anti-IL-23 receptor monoclonal antibody prevents CD4(+) T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses. Eur J Pharmacol. 2018;824:163–9.PubMedCrossRef
78.
Zurück zum Zitat Eftychi C, Schwarzer R, Vlantis K, et al. Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment. Immunity. 2019;51:367-80.e364.PubMedCrossRef Eftychi C, Schwarzer R, Vlantis K, et al. Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment. Immunity. 2019;51:367-80.e364.PubMedCrossRef
79.
Zurück zum Zitat Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.PubMedCrossRef Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.PubMedCrossRef
80.
Zurück zum Zitat Ramanan D, Tang MS, Bowcutt R, et al. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity. 2014;41:311–24.PubMedPubMedCentralCrossRef Ramanan D, Tang MS, Bowcutt R, et al. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal Bacteroides vulgatus. Immunity. 2014;41:311–24.PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Wang H, Zhang X, Zuo Z, et al. Rip2 is required for Nod2-mediated lysozyme sorting in Paneth cells. J Immunol. 2017;198:3729–36.PubMedCrossRef Wang H, Zhang X, Zuo Z, et al. Rip2 is required for Nod2-mediated lysozyme sorting in Paneth cells. J Immunol. 2017;198:3729–36.PubMedCrossRef
82.
Zurück zum Zitat Alnabhani Z, Hugot JP, Montcuquet N, et al. Respective roles of hematopoietic and nonhematopoietic Nod2 on the gut microbiota and mucosal homeostasis. Inflamm Bowel Dis. 2016;22:763–73.PubMedCrossRef Alnabhani Z, Hugot JP, Montcuquet N, et al. Respective roles of hematopoietic and nonhematopoietic Nod2 on the gut microbiota and mucosal homeostasis. Inflamm Bowel Dis. 2016;22:763–73.PubMedCrossRef
83.
Zurück zum Zitat Prescott D, Maisonneuve C, Yadav J, et al. NOD2 modulates immune tolerance via the GM-CSF-dependent generation of CD103(+) dendritic cells. Proc Natl Acad Sci USA. 2020;117:10946–57.PubMedPubMedCentralCrossRef Prescott D, Maisonneuve C, Yadav J, et al. NOD2 modulates immune tolerance via the GM-CSF-dependent generation of CD103(+) dendritic cells. Proc Natl Acad Sci USA. 2020;117:10946–57.PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Kramer M, Netea MG, de Jong DJ, et al. Impaired dendritic cell function in Crohn’s disease patients with NOD2 3020insC mutation. J Leukoc Biol. 2006;79:860–6.PubMedCrossRef Kramer M, Netea MG, de Jong DJ, et al. Impaired dendritic cell function in Crohn’s disease patients with NOD2 3020insC mutation. J Leukoc Biol. 2006;79:860–6.PubMedCrossRef
86.
Zurück zum Zitat Neurath MF, Pettersson S, Meyerzum Büschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998–1004.PubMedCrossRef Neurath MF, Pettersson S, Meyerzum Büschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998–1004.PubMedCrossRef
88.
Zurück zum Zitat Pallone F, Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol. 2001;17:307–12.PubMedCrossRef Pallone F, Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol. 2001;17:307–12.PubMedCrossRef
89.
Zurück zum Zitat Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557–61.PubMedCrossRef Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557–61.PubMedCrossRef
90.
Zurück zum Zitat Arsura M, Wu M, Sonenshein GE. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity. 1996;5:31–40.PubMedCrossRef Arsura M, Wu M, Sonenshein GE. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity. 1996;5:31–40.PubMedCrossRef
91.
Zurück zum Zitat Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601–9.PubMedPubMedCentralCrossRef Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601–9.PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7:16–26.PubMedCrossRef Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7:16–26.PubMedCrossRef
93.
Zurück zum Zitat Ihara S, Hirata Y, Serizawa T, et al. TGF-β Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. J Immunol. 2016;196:4603–13.PubMedCrossRef Ihara S, Hirata Y, Serizawa T, et al. TGF-β Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota. J Immunol. 2016;196:4603–13.PubMedCrossRef
95.
Zurück zum Zitat Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol. 2017;52:777–87.PubMedCrossRef Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol. 2017;52:777–87.PubMedCrossRef
96.
Zurück zum Zitat Zheng CF. Huang Y [Expression of zinc finger protein A20 in pediatric inflammatory bowel disease]. Zhonghua Er Ke Za Zhi. 2011;49:261–5.PubMed Zheng CF. Huang Y [Expression of zinc finger protein A20 in pediatric inflammatory bowel disease]. Zhonghua Er Ke Za Zhi. 2011;49:261–5.PubMed
97.
Zurück zum Zitat Majumdar I, Ahuja V, Paul J. Altered expression of tumor necrosis factor alpha-induced protein 3 correlates with disease severity in ulcerative colitis. Sci Rep. 2017;7:9420.PubMedPubMedCentralCrossRef Majumdar I, Ahuja V, Paul J. Altered expression of tumor necrosis factor alpha-induced protein 3 correlates with disease severity in ulcerative colitis. Sci Rep. 2017;7:9420.PubMedPubMedCentralCrossRef
98.
Zurück zum Zitat Chen D, Ma L, Hu T, et al. A20 restores impaired intestinal permeability and inhibits Th2 response in mice with colitis. Dig Dis Sci. 2020;65:1340–7.PubMedCrossRef Chen D, Ma L, Hu T, et al. A20 restores impaired intestinal permeability and inhibits Th2 response in mice with colitis. Dig Dis Sci. 2020;65:1340–7.PubMedCrossRef
99.
Zurück zum Zitat Hu T, Hu W, Ma L, et al. pVAX1-A20 alleviates colitis in mice by promoting regulatory T cells. Dig Liver Dis. 2019;51:790–7.PubMedCrossRef Hu T, Hu W, Ma L, et al. pVAX1-A20 alleviates colitis in mice by promoting regulatory T cells. Dig Liver Dis. 2019;51:790–7.PubMedCrossRef
100.
Zurück zum Zitat Kolodziej LE, Lodolce JP, Chang JE, et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS ONE. 2011;6: e26352.PubMedPubMedCentralCrossRef Kolodziej LE, Lodolce JP, Chang JE, et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS ONE. 2011;6: e26352.PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Hammer GE, Turer EE, Taylor KE, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. 2011;12:1184–93.PubMedPubMedCentralCrossRef Hammer GE, Turer EE, Taylor KE, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. 2011;12:1184–93.PubMedPubMedCentralCrossRef
102.
Zurück zum Zitat Tai Y, Wang Q, Korner H, et al. Molecular mechanisms of T cells activation by Dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642.PubMedPubMedCentralCrossRef Tai Y, Wang Q, Korner H, et al. Molecular mechanisms of T cells activation by Dendritic cells in autoimmune diseases. Front Pharmacol. 2018;9:642.PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Wakkach A, Fournier N, Brun V, et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18:605–17.PubMedCrossRef Wakkach A, Fournier N, Brun V, et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity. 2003;18:605–17.PubMedCrossRef
104.
Zurück zum Zitat Skovdahl HK, Granlund A, Østvik AE, et al. Expression of CCL20 and its corresponding receptor CCR6 is enhanced in active inflammatory bowel disease, and TLR3 mediates CCL20 expression in colonic epithelial cells. PLoS ONE. 2015;10: e0141710.PubMedPubMedCentralCrossRef Skovdahl HK, Granlund A, Østvik AE, et al. Expression of CCL20 and its corresponding receptor CCR6 is enhanced in active inflammatory bowel disease, and TLR3 mediates CCL20 expression in colonic epithelial cells. PLoS ONE. 2015;10: e0141710.PubMedPubMedCentralCrossRef
Metadaten
Titel
Inflammatory Gene Panel Guiding the Study of Genetics in Inflammatory Bowel Disease
verfasst von
Ryan Xin
Publikationsdatum
18.04.2024
Verlag
Springer International Publishing
Erschienen in
Molecular Diagnosis & Therapy / Ausgabe 4/2024
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-024-00709-x

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Dank Nasenspray seltener in die Notaufnahme

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.